OnCo

HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumour-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognised by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Location: Cell membrane; Endoplasmic reticulum membrane (UniProt). Locus 6p21.33 (HGNC).

Where it is found
  • Cervical cancer: IntOGen driver in 1 cohort (CESC)
  • Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
  • Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
  • Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)
  • Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)
  • Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
Class: tumor suppressor · Gene: HLA-B · Facts checked 2026-09-23 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"HLA-B" OR ABSTRACT:"HLA-B" OR TITLE:"major histocompatibility complex, class I, B" OR ABSTRACT:"major histocompatibility complex, class I, B" OR TITLE:"HLA class I histocompatibility antigen, B alpha chain" OR ABSTRACT:"HLA class I histocompatibility antigen, B alpha chain") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-B, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/hla-b.json. Licence CC BY-NC 4.0.